focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,812.50
Bid: 1,812.50
Ask: 1,813.00
Change: 2.50 (0.14%)
Spread: 0.50 (0.028%)
Open: 1,811.00
High: 1,820.00
Low: 1,803.00
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European shares fall as healthcare stocks hit by drug reforms

Wed, 26th Apr 2023 17:48

Healthcare index marks biggest decline in 15 months

*

ASM falls after drop in Q1 orders

*

Temenos jumps on Q1 earnings beat

April 26 (Reuters) - European shares closed lower for the second straight session on Wednesday, weighed down by a slide in healthcare stocks after Brussels published a long-awaited draft of its proposed overhaul of laws governing the European Union's pharmaceuticals industry.

The pan-European STOXX 600 index fell 0.8%, with healthcare stocks tumbling 2.5%, clocking its worst performance since late January, 2022.

The proposal, which is the biggest overhaul of existing medical laws in two decades, is aimed at ensuring all Europeans have access to both innovative new treatments and generic drugs, and ending huge divergences in access and price between countries.

"It's all about trying to get healthcare costs down, and at the end of the day that really translates as spending less. And of course, the read-across is less money available in the industry for spending on drugs and medical products etc," said Stuart Cole, chief macro economist at Equiti Capital.

Shares of some of Europe's biggest drugmakers including Roche, Novo Nordisk, GSK and AstraZeneca fell between 2.5% and 3.9%.

Earnings from the sector was mixed, with Roche reporting a drop in first-quarter sales, while GSK beat quarterly analyst expectations.

The STOXX 600 index is still tracking monthly gains of 1.1% as more earnings pour in.

Telia Company AB rose 5.3% after the Swedish telecom operator posted first-quarter core earnings above market expectations.

Shares of Swiss banking software company Temenos AG jumped 13.4% after it reported first-quarter earnings above consensus.

Kindred Group Plc jumped 16.0% after the company initiated a review of strategic alternatives, including a merger or sale of the company.

ASM International NV fell 7.5% after the Dutch semiconductor equipment maker reported a drop in first-quarter orders, citing softening market conditions, despite an estimate-beating revenue.

Dassault Systemes SE slid 6.8% after the French software maker reported first-quarter numbers broadly in line with estimates but with a miss on software licences.

Teleperformance SE slumped 14.0%, to the bottom of the STOXX 600, after the French outsourcing group said it intends to buy rival Majorel Group Luxembourg SA for 3 billion euros ($3.3 billion).

Investors now await the European Central Bank's monetary policy meeting next week. A Reuters poll of economists suggested that ECB will almost certainly add 25 basis points to its deposit rate on May 4 and then take it to 3.50% or higher in June. (Reporting by Shreyashi Sanyal in Bengaluru; Additional reporting by Shubham Batra; Editing by Sherry Jacob-Phillips, Sonia Cheema and Alison Williams)

More News
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.